BioNTech Shares Fall After BMO Downgrade and Price Target Cut

Recent market activity shows a decline in shares for several biotechnology companies. BioNTech experienced a stock drop following a BMO downgrade and a reduction in its price target. Similarly, Amgen shares fell as investors evaluated Novartis Lp(a) trial results alongside a BMO downgrade. Additionally, Biohaven shares decreased after RBC downgraded the stock and lowered its price target. These movements reflect investor reactions to analyst revisions and clinical trial outcomes across the pharmaceutical sector.